{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-323850","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.864597+00:00","generated_at":"2026-06-28T10:39:50.182926+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Synlogic and Ginkgo announce clinical candidate SYNB1353 for homocystinuria; IND filing expected 2022","bullets":["SYNB1353 is an investigational Synthetic Biotic medicine for homocystinuria (HCU), developed using Synlogic's platform and Ginkgo's codebase.","First candidate from Synlogic-Ginkgo collaboration to enter IND-enabling studies.","Synlogic expects to file an IND with FDA and begin clinical development in 2022.","Preclinical data to be presented at International Congress of Inborn Errors of Metabolism 2021 (Nov 21-23)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-323850","json":"https://secwatch.observer/filing/0001193125-21-323850.json","markdown":"https://secwatch.observer/filing/0001193125-21-323850.md","text":"https://secwatch.observer/filing/0001193125-21-323850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000119312521323850/0001193125-21-323850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000119312521323850/d232569d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:39:50.182926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}